Immunic Inc (NASDAQ:IMUX)
| 2.24 Delayed Data As of Jan 27 |  0.00 / 0.00%Today’s Change | 1.11 Today|||52-Week Range 14.50 | +60.00% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $82.9M |
Company Description
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
Contact Information
Immunic, Inc. 1200 Avenue of the Americas New York New York 10036 |
Employees
Shareholders
| Other institutional | 46.20% |
| Mutual fund holders | 3.62% |
| Individual stakeholders | 2.45% |
Top Executives
| Daniel Vitt | President, Chief Executive Officer & Director |
| Manfred Gröppel | Chief Operating Officer |
| Glenn Whaley | Chief Financial Officer |
| Andreas Muehler | Chief Medical Officer |
| Hella Kohlhof | Chief Scientific Officer |
